U.S. patent application number 14/105517 was filed with the patent office on 2014-04-17 for new compounds ii.
This patent application is currently assigned to Proximagen Ltd. The applicant listed for this patent is Proximagen Ltd. Invention is credited to Edward Savory, Iain Simpson.
Application Number | 20140107150 14/105517 |
Document ID | / |
Family ID | 41226934 |
Filed Date | 2014-04-17 |
United States Patent
Application |
20140107150 |
Kind Code |
A1 |
Savory; Edward ; et
al. |
April 17, 2014 |
New Compounds II
Abstract
The present invention relates to compounds of formula (I),
##STR00001## and their pharmaceutically acceptable salts, solvates,
hydrates, geometrical isomers, tautomers, optical isomers or
N-oxides, which are inhibitors of SSAO activity. The invention
further relates to pharmaceutical compositions comprising these
compounds and to the use of these compounds for the treatment of
medical conditions wherein inhibition of SSAO activity is
beneficial, such as such as inflammatory diseases and immune
disorders.
Inventors: |
Savory; Edward;
(Cambridgeshire, GB) ; Simpson; Iain;
(Cambridgeshire, GB) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Proximagen Ltd |
London |
|
GB |
|
|
Assignee: |
Proximagen Ltd
London
GB
|
Family ID: |
41226934 |
Appl. No.: |
14/105517 |
Filed: |
December 13, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13062366 |
Apr 26, 2011 |
8633318 |
|
|
PCT/EP09/62018 |
Sep 16, 2009 |
|
|
|
14105517 |
|
|
|
|
61106727 |
Oct 20, 2008 |
|
|
|
Current U.S.
Class: |
514/303 ;
546/119 |
Current CPC
Class: |
A61P 9/00 20180101; A61P
25/00 20180101; A61P 25/28 20180101; A61P 43/00 20180101; A61P 3/10
20180101; C07D 471/04 20130101; A61P 17/06 20180101; A61P 31/04
20180101; A61P 1/04 20180101; A61P 11/16 20180101; A61P 37/02
20180101; A61P 11/00 20180101; A61P 1/16 20180101; A61P 17/00
20180101; A61P 9/10 20180101; A61P 29/00 20180101; A61P 11/06
20180101; A61P 9/04 20180101; A61P 19/02 20180101 |
Class at
Publication: |
514/303 ;
546/119 |
International
Class: |
C07D 471/04 20060101
C07D471/04 |
Foreign Application Data
Date |
Code |
Application Number |
Sep 16, 2008 |
SE |
0801980.4 |
Claims
1. A compound of formula (I), ##STR00030## or a pharmaceutically
acceptable salt, geometrical isomer, tautomer, optical isomer or
N-oxide thereof, wherein: R.sup.1 is one, two or three substituents
independently selected from halogen, cyano, C.sub.1-6-alkyl,
halo-C.sub.1-6-alkyl and C.sub.1-6-alkoxy; R.sup.2 is a 4- to
7-membered saturated or partially saturated heterocyclic ring
containing 1 or 2 heteroatoms independently selected from O, S and
N(R.sup.3), and wherein ring carbon atoms are optionally
substituted with R.sup.4; R.sup.3 is selected from hydrogen,
C.sub.1-6-alkyl, hydroxy-C.sub.1-6-alkyl, cyano-C.sub.1-6-alkyl,
halo-C.sub.1-6-alkyl, C.sub.1-6-alkoxy-C.sub.1-6-alkyl,
C.sub.1-6-acyl and C.sub.1-6-alkylsulfonyl; R.sup.4 is selected
from halogen, hydroxy, C.sub.1-6-alkyl, hydroxy-C.sub.1-6-alkyl,
C.sub.1-6-alkoxy-C.sub.1-6-alkyl, cyano-C.sub.1-6-alkyl,
halo-C.sub.1-6-alkyl and C.sub.1-6-alkoxy; and a is 0, 1 or 2;
provided that the compound is not:
3-(3,4-dichlorophenyl)-1-(1-methylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyrid-
ine, or
1-(1-methylpiperidin-4-yl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazo-
lo[4,3-c]-pyridine.
2. A compound according to claim 1 having formula (I'),
##STR00031## wherein R.sup.1 is selected from halogen, cyano and
C.sub.1-4-alkyl; R.sup.2 is a 5- to 6-membered saturated or
partially saturated heterocyclic ring containing 1 or 2 heteroatoms
independently selected from O, S and N(R.sup.3), and wherein ring
carbon atoms are optionally substituted with R.sup.4; R.sup.3 is
selected from hydrogen, C.sub.1-4-alkyl, hydroxy-C.sub.1-4-alkyl,
cyano-C.sub.1-4-alkyl, halo-C.sub.1-4-alkyl,
C.sub.1-4-alkoxy-C.sub.1-4-alkyl, C.sub.1-4-acyl and
C.sub.1-4-alkylsulfonyl; R.sup.4, if present, is independently
selected from C.sub.1-4-alkyl, halo-C.sub.1-4-alkyl,
hydroxy-C.sub.14-alkyl and C.sub.1-4-alkoxy-C.sub.1-4-alkyl; and a
is 0 or 1.
3. A compound according to claim 1 having formula (I''),
##STR00032## wherein R.sup.1 is selected from halogen, cyano and
C.sub.1-4-alkyl; R.sup.2 is a saturated 5- to 6-membered
heterocyclic ring containing 1 heteroatom selected from O and
N(R.sup.3), and wherein ring carbon atoms are optionally
substituted with R.sup.4; R.sup.3 is hydrogen, C.sub.1-4-alkyl or
cyano-C.sub.1-4-alkyl; and R.sup.4, if present, is independently
methyl or ethyl.
4. A compound according to claim 1, which is selected from:
3-(4-Fluorophenyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[4,3-c]pyridin-
e;
3-(4-Chlorophenyl)-2-(tetrahydro-2H-pyran-4-yl)-2H-pyrazolo[4,3-c]pyrid-
ine;
3-(4-Methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[4,3-c]pyr-
idine;
3-(4-Chlorophenyl)-1-[(3R)-tetrahydrofuran-3-yl]-1H-pyrazolo[4,3-c]-
pyridine;
3-(4-Chlorophenyl)-1-piperidin-4-yl-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chlorophenyl)-1-(1-methylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridine;
{4-[3-(4-Chlorophenyl)-1H-pyrazolo[4,3-c]pyridin-1-yl]piperidin-1-yl}-ace-
tonitrile;
3-(4-Chlorophenyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazo-
lo[4,3-c]-pyridine;
3-(4-Chlorophenyl)-1-[1-(methylsulfonyl)piperidin-4-yl]-1H-pyrazolo[4,3-c-
]-pyridine;
1-(1-Acetylpiperidin-4-yl)-3-(4-chlorophenyl)-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chlorophenyl)-1-[1-(2-methoxyethyl)piperidin-4-yl]-1H-pyrazolo[4,3-c-
]-pyridine;
3-(4-Chlorophenyl)-1-piperidin-3-yl-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chlorophenyl)-1-[(3S)-tetrahydrofuran-3-yl]-1H-pyrazolo[4,3-c]pyridi-
ne;
3-(4-Chlorophenyl)-1-(tetrahydrofuran-3-ylmethyl)-1H-pyrazolo[4,3-c]py-
ridine;
3-(4-Chlorophenyl)-1-(1-ethylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyr-
idine;
3-(4-Chlorophenyl)-1-(1-isopropylpiperidin-4-yl)-1H-pyrazolo[4,3-c]-
pyridine;
3-(4-Fluorophenyl)-1-(1-methylpiperidin-4-yl)-1H-pyrazolo[4,3-c]-
pyridine;
3-(4-Fluorophenyl)-1-piperidin-4-yl-1H-pyrazolo[4,3-c]pyridine;
4-[1-(Tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl]benzonitri-
le; and
4-[1-(1-Methylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl]benzo-
nitrile.
5. A pharmaceutical formulation comprising a compound according to
claim 1 as an active ingredient, in combination with a
pharmaceutically acceptable diluent or carrier.
6. The pharmaceutical formulation of claim 5 wherein the active
ingredient is present in an effective amount for the treatment of
inflammation, an inflammatory disease, an immune or an autoimmune
disorder.
7. The pharmaceutical formulation according to claim 6, wherein the
inflammation or inflammatory disease or immune or autoimmune
disorder is arthritis, synovitis, vasculitis, a condition
associated with inflammation of the bowel, atherosclerosis,
multiple sclerosis, Alzheimer's disease, vascular dementia, a
pulmonary inflammatory disease, a fibrotic disease, an inflammatory
disease of the skin, systemic inflammatory response syndrome,
sepsis, an inflammatory and/or autoimmune condition of the liver,
diabetes (type I or II) and/or the complications thereof, chronic
heart failure, congestive heart failure, an ischemic disease or
myocardial infarction and/or the complications thereof.
8. The pharmaceutical formulation according to claim 6, wherein the
inflammatory disease is vasculitis.
9. The pharmaceutical formulation according to claim 6, wherein the
inflammation or inflammatory disease or immune or autoimmune
disorder is rheumatoid arthritis, juvenile rheumatoid arthritis,
osteoarthritis, psoriatic arthritis, Crohn's disease, ulcerative
colitis, inflammatory bowel disease, irritable bowel syndrome,
asthma, chronic obstructive pulmonary disease, acute respiratory
distress syndrome, idiopathic pulmonary fibrosis, cardiac fibrosis,
systemic sclerosis, contact dermatitis, atopic dermatitis,
psoriasis, autoimmune hepatitis, primary biliary cirrhosis,
alcoholic liver disease, sclerosing cholangitis, autoimmune
cholangitis, stroke, or ischemia-reperfusion injury.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional application of U.S. Ser.
No. 13/062,366, filed Mar. 4, 2011, now allowed, which is a
National Stage application of co-pending PCT application
PCT/EP2009/062018 filed Sep. 16, 2009, which application claims
priority from SE Application No. 0801980-4 filed Sep. 16, 2008, and
U.S. Ser. No. 61/106,727 filed Oct. 20, 2008. The above mentioned
applications are incorporated herein by reference in their
entirety.
FIELD OF THE INVENTION
[0002] The present invention relates to new pyrazolo[4,3-c]pyridine
compounds of formula (I), which are inhibitors of SSAO activity.
The invention also relates to pharmaceutical compositions
comprising these compounds and to the use of these compounds in the
treatment or prevention of medical conditions wherein inhibition of
SSAO activity is beneficial, such as such as inflammatory diseases
and immune disorders.
BACKGROUND ART
[0003] Semicarbazide-sensitive amine oxidase (SSAO), otherwise
known as Vascular Adhesion Protein-1 (VAP-1) or Amine Oxidase,
Copper Containing 3 (AOC3), belongs to the copper-containing amine
oxidase family of enzymes (EC.1.4.3.6). Members of this enzyme
family are sensitive to inhibition by semicarbazide and utilize
cupric ion and protein-derived topa quinone (TPQ) cofactor in the
oxidative deamination of primary amines to aldehydes, hydrogen
peroxide, and ammonia according to the following reaction:
RCH.sub.2NH.sub.2+O.sub.2.fwdarw.R--CHO+H.sub.2O.sub.2+NH.sub.3
[0004] Known substrates for human SSAO include endogenous
methylamine and aminoacetone as well as some xenobiotic amines such
as benzylamine [Lyles, Int. J. Biochem. Cell Biol. 1996, 28,
259-274; Klinman, Biochim. Biophys. Acta 2003, 1647(1-2), 131-137;
Matyus et al., Curr. Med. Chem. 2004, 11(10), 1285-1298; O'Sullivan
et al., Neurotoxicology 2004, 25(1-2), 303-315]. In analogy with
other copper-containing amine oxidases, DNA-sequence analysis and
structure determination suggest that the tissue-bound human SSAO is
a homodimeric glycoprotein consisting of two 90-100 kDa subunits
anchored to the plasma membrane by a single N-terminal membrane
spanning domain [Morris et al., J. Biol. Chem. 1997, 272,
9388-9392; Smith et al., J. Exp. Med. 1998, 188, 17-27; Airenne et
al., Protein Science 2005, 14, 1964-1974; Jakobsson et al., Acta
Crystallogr. D Biol. Crystallogr. 2005, 61(Pt 11), 1550-1562].
[0005] SSAO activity has been found in a variety of tissues
including vascular and non-vascular smooth muscle tissue,
endothelium, and adipose tissue [Lewinsohn, Braz. J. Med. Biol.
Res. 1984, 17, 223-256; Nakos & Gossrau, Folia Histochem.
Cytobiol. 1994, 32, 3-10; Yu et al., Biochem. Pharmacol. 1994, 47,
1055-1059; Castillo et al., Neurochem. Int. 1998, 33, 415-423;
Lyles & Pino, J. Neural. Transm. Suppl. 1998, 52, 239-250;
Jaakkola et al., Am. J. Pathol. 1999, 155, 1953-1965; Morin et al.,
J. Pharmacol. Exp. Ther. 2001, 297, 563-572; Salmi & Jalkanen,
Trends Immunol. 2001, 22, 211-216]. In addition, SSAO protein is
found in blood plasma and this soluble form appears to have similar
properties as the tissue-bound form [Yu et al., Biochem. Pharmacol.
1994, 47, 1055-1059; Kurkijarvi et al., J. Immunol. 1998, 161,
1549-1557]. It has recently been shown that circulating human and
rodent SSAO originates from the tissue-bound form [Gokturk et al.,
Am. J. Pathol. 2003, 163(5), 1921-1928; Abella et al., Diabetologia
2004, 47(3), 429-438; Stolen et al., Circ. Res. 2004, 95(1),
50-57], whereas in other mammals the plasma/serum SSAO is also
encoded by a separate gene called AOC4 [Schwelberger, J. Neural.
Transm. 2007, 114(6), 757-762].
[0006] The precise physiological role of this abundant enzyme has
yet to be fully determined, but it appears that SSAO and its
reaction products may have several functions in cell signalling and
regulation. For example, recent findings suggest that SSAO plays a
role in both GLUT4-mediated glucose uptake [Enrique-Tarancon et
al., J. Biol. Chem. 1998, 273, 8025-8032; Morin et al., J.
Pharmacol. Exp. Ther. 2001, 297, 563-572] and adipocyte
differentiation [Fontana et al., Biochem. J. 2001, 356, 769-777;
Mercier et al., Biochem. J. 2001, 358, 335-342]. In addition, SSAO
has been shown to be involved in inflammatory processes where it
acts as an adhesion protein for leukocytes [Salmi & Jalkanen,
Trends Immunol. 2001, 22, 211-216; Salmi & Jalkanen, in
"Adhesion Molecules: Functions and Inhibition" K. Ley (Ed.), 2007,
pp. 237-251], and might also play a role in connective tissue
matrix development and maintenance [Langford et al., Cardiovasc.
Toxicol. 2002, 2(2), 141-150; Gokturk et al., Am. J. Pathol. 2003,
163(5), 1921-1928]. Moreover, a link between SSAO and angiogenesis
has recently been discovered [Noda et al., FASEB J. 2008, 22(8),
2928-2935].
[0007] Several studies in humans have demonstrated that SSAO
activity in blood plasma is elevated in conditions such as
congestive heart failure, diabetes mellitus, Alzheimer's disease,
and inflammation [Lewinsohn, Braz. J. Med. Biol. Res. 1984, 17,
223-256; Boomsma et al., Cardiovasc. Res. 1997, 33, 387-391;
Ekblom, Pharmacol. Res. 1998, 37, 87-92; Kurkijarvi et al., J.
Immunol. 1998, 161, 1549-1557; Boomsma et al., Diabetologia 1999,
42, 233-237; Meszaros et al., Eur. J. Drug Metab. Pharmacokinet.
1999, 24, 299-302; Yu et al., Biochim. Biophys. Acta 2003,
1647(1-2), 193-199; Matyus et al., Curr. Med. Chem. 2004, 11(10),
1285-1298; O'Sullivan et al., Neurotoxicology 2004, 25(1-2),
303-315; del Mar Hernandez et al., Neurosci. Lett. 2005, 384(1-2),
183-187]. The mechanisms underlying these alterations of enzyme
activity are not clear. It has been suggested that reactive
aldehydes and hydrogen peroxide produced by endogenous amine
oxidases contribute to the progression of cardiovascular diseases,
diabetic complications and Alzheimer's disease [Callingham et al.,
Prog. Brain Res. 1995, 106, 305-321; Ekblom, Pharmacol. Res. 1998,
37, 87-92; Yu et al., Biochim. Biophys. Acta 2003, 1647(1-2),
193-199; Jiang et al., Neuropathol Appl Neurobiol. 2008, 34(2),
194-204]. Furthermore, the enzymatic activity of SSAO is involved
in the leukocyte extravasation process at sites of inflammation
where SSAO has been shown to be strongly expressed on the vascular
endothelium [Salmi et al., Immunity 2001, 14(3), 265-276; Salmi
& Jalkanen, in "Adhesion Molecules: Functions and Inhibition"
K. Ley (Ed.), 2007, pp. 237-251]. Accordingly, inhibition of SSAO
has been suggested to have a therapeutic value in the prevention of
diabetic complications and in inflammatory diseases [Ekblom,
Pharmacol. Res. 1998, 37, 87-92; Salmi et al., Immunity 2001,
14(3), 265-276; Salter-Cid et al., J. Pharmacol. Exp. Ther. 2005,
315(2), 553-562].
[0008] SSAO knockout animals are phenotypically overtly normal but
exhibit a marked decrease in the inflammatory responses evoked in
response to various inflammatory stimuli [Stolen et al., Immunity
2005, 22(1), 105-115]. In addition, antagonism of its function in
wild type animals in multiple animal models of human disease (e.g.
carrageenan-induced paw inflammation, oxazolone-induced colitis,
lipopolysaccharide-induced lung inflammation, collagen-induced
arthritis, endotoxin-induced uveitis) by the use of antibodies
and/or small molecules has been shown to be protective in
decreasing the leukocyte infiltration, reducing the severity of the
disease phenotype and reducing levels of inflammatory cytokines and
chemokines [Kirton et al., Eur. J. Immunol. 2005, 35(11),
3119-3130; Salter-Cid et al., J. Pharmacol. Exp. Ther. 2005,
315(2), 553-562; McDonald et al., Annual Reports in Medicinal
Chemistry 2007, 42, 229-243; Salmi & Jalkanen, in "Adhesion
Molecules: Functions and Inhibition" K. Ley (Ed.), 2007, pp.
237-251; Noda et al., FASEB J. 2008 22(4), 1094-1103; Noda et al.,
FASEB J. 2008, 22(8), 2928-2935]. This anti-inflammatory protection
seems to be afforded across a wide range of inflammatory models all
with independent causative mechanisms, rather than being restricted
to one particular disease or disease model. This would suggest that
SSAO may be a key nodal point for the regulation of the
inflammatory response, and it therefore seems likely that SSAO
inhibitors may be effective anti-inflammatory drugs in a wide range
of human diseases.
[0009] The invention described here relates to novel
pyrazolo[4,3-c]pyridine derivatives as a new class of chemically
distinct SSAO inhibitors with biological, pharmacological, and
pharmacokinetic characteristics that make them suitable for use as
prophylactic or therapeutic agents in a wide range of human
inflammatory diseases and immune disorders. This therapeutic
capacity is designed to block SSAO enzyme action, reducing the
levels of pro-inflammatory enzyme products (aldehydes, hydrogen
peroxide and ammonia) whilst also decreasing the adhesive capacity
of immune cells and correspondingly their activation and final
extra-vasation. Diseases where such an activity is expected to be
therapeutically beneficial include all diseases where immune cells
play a prominent role in the initiation, maintenance or resolution
of the pathology, such as multiple sclerosis, arthritis and
vasculitis.
[0010] Pyrazolo[4,3-c]pyridine compounds have been disclosed in WO
94/03453 as angiotensin II receptor antagonists for use in the
treatment of hypertension and congestive heart failure. EP 594001
describes 4-phenylpyrazolo[4,3-c]pyridine compounds as serotonin
reuptake inhibitors for use in the treatment of depression and
obsessive competitive disorder. SSAO inhibitors have been described
in WO 02/38153, which discloses certain
tetrahydroimidazo[4,5-c]pyridine derivatives that are useful in the
treatment of diabetes and vascular complications.
DISCLOSURE OF THE INVENTION
[0011] It has surprisingly been found that the new
pyrazolo[4,3-c]pyridine compounds of formula (I) are inhibitors of
SSAO activity. They are therefore useful in the treatment or
prevention of diseases in which inhibition of SSAO activity is
beneficial. As such they are potentially useful for the treatment
or prevention of inflammation, inflammatory diseases, immune or
autoimmune disorders. Consequently, the invention relates to a
compound of formula (I),
##STR00002##
or a pharmaceutically acceptable salt, solvate, hydrate,
geometrical isomer, tautomer, optical isomer or N-oxide thereof,
wherein: R.sup.1 is one, two or three substituents independently
selected from halogen, cyano, C.sub.1-6-alkyl, halo-C.sub.1-6-alkyl
and C.sub.1-6-alkoxy; R.sup.2 is a 4- to 7-membered heterocyclic
ring containing 1 or 2 heteroatoms independently selected from O, S
and N(R.sup.3), and wherein ring carbon atoms are optionally
substituted with R.sup.4; R.sup.3 is selected from hydrogen,
C.sub.1-6-alkyl, hydroxy-C.sub.1-6-alkyl, cyano-C.sub.1-6-alkyl,
halo-C.sub.1-6-alkyl, C.sub.1-6-alkoxy-C.sub.1-6-alkyl,
C.sub.1-6-acyl and C.sub.1-6-alkylsulfonyl; R.sup.4 is
independently selected from halogen, hydroxy, C.sub.1-6-alkyl,
hydroxy-C.sub.1-6-alkyl, C.sub.1-6-alkoxy-C.sub.1-6-alkyl,
cyano-C.sub.1-6-alkyl, halo-C.sub.1-6-alkyl and C.sub.1-6-alkoxy;
and a is 0, 1 or 2; provided that the compound is not: [0012]
3-(3,4-dichlorophenyl)-1-(1-methylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyrid-
ine, or [0013]
1-(1-methylpiperidin-4-yl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3--
c]pyridine.
[0014] More preferred compounds of formula (I) are those
wherein:
R.sup.1 is selected from halogen, cyano and C.sub.1-4-alkyl; and
R.sup.2 is a 5- to 6-membered heterocyclic ring containing 1 or 2
heteroatoms independently selected from O, S and N(R.sup.3), and
wherein ring carbon atoms are optionally substituted with
R.sup.4.
[0015] A preferred embodiment of the invention consists of
compounds of formula (I'),
##STR00003##
wherein R.sup.1 is selected from halogen, cyano and
C.sub.1-4-alkyl; R.sup.2 is a 5- to 6-membered heterocyclic ring
containing 1 or 2 heteroatoms independently selected from O, S and
N(R.sup.3), and wherein ring carbon atoms are optionally
substituted with R.sup.4; R.sup.3 is selected from hydrogen,
C.sub.1-4-alkyl, hydroxy-C.sub.1-4-alkyl, cyano-C.sub.1-4-alkyl,
halo-C.sub.1-4-alkyl, C.sub.1-4-alkoxy-C.sub.1-4-alkyl,
C.sub.1-4-acyl and C.sub.1-4-alkylsulfonyl; R.sup.4, if present, is
independently selected from C.sub.1-4-alkyl, halo-C.sub.1-4-alkyl,
hydroxy-C.sub.1-4-alkyl and C.sub.1-4-alkoxy-C.sub.14-alkyl; and a
is 0 or 1.
[0016] A further preferred embodiment of the invention consists of
compounds of formula (I''),
##STR00004##
wherein R.sup.1 is selected from halogen, cyano and
C.sub.1-4-alkyl; R.sup.2 is a saturated 5- to 6-membered
heterocyclic ring containing 1 heteroatom selected from O and
N(R.sup.3), and wherein ring carbon atoms are optionally
substituted with R.sup.4; R.sup.3 is hydrogen, C.sub.1-4-alkyl or
cyano-C.sub.1-4-alkyl; R.sup.4, if present, is independently methyl
or ethyl.
[0017] Even more preferred compounds of formula (I'') are those
wherein:
R.sup.1 is fluoro, chloro or methyl; R.sup.2 is a piperidine,
tetrahydropyran or tetrahydrofuran ring; R.sup.3, if present, is
hydrogen, methyl or cyanomethyl; and R.sup.4 is absent.
[0018] Specific preferred compounds of the invention are selected
from the group consisting of: [0019]
3-(4-Fluorophenyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[4,3-c]pyridin-
e; [0020]
3-(4-Chlorophenyl)-2-(tetrahydro-2H-pyran-4-yl)-2H-pyrazolo[4,3--
c]pyridine; [0021]
3-(4-Methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[4,3-c]pyridin-
e; [0022]
3-(4-Chlorophenyl)-1-[(3R)-tetrahydrofuran-3-yl]-1H-pyrazolo[4,3-
-c]pyridine; [0023]
3-(4-Chlorophenyl)-1-piperidin-4-yl-1H-pyrazolo[4,3-c]pyridine;
[0024]
3-(4-Chlorophenyl)-1-(1-methylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridine;
[0025]
{4-[3-(4-Chlorophenyl)-1H-pyrazolo[4,3-c]pyridin-1-yl]piperidin-1--
yl}acetonitrile; [0026]
3-(4-Chlorophenyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazolo[4,3-c]p-
yridine; [0027]
3-(4-Chlorophenyl)-1-[1-(methylsulfonyl)piperidin-4-yl]-1H-pyrazolo[4,3-c-
]pyridine; [0028]
1-(1-Acetylpiperidin-4-yl)-3-(4-chlorophenyl)-1H-pyrazolo[4,3-c]pyridine;
[0029]
3-(4-Chlorophenyl)-1-[1-(2-methoxyethyl)piperidin-4-yl]-1H-pyrazol-
o[4,3-c]pyridine; [0030]
3-(4-Chlorophenyl)-1-piperidin-3-yl-1H-pyrazolo[4,3-c]pyridine;
[0031]
3-(4-Chlorophenyl)-1-[(3S)-tetrahydrofuran-3-yl]-1H-pyrazolo[4,3-c]pyridi-
ne; [0032]
3-(4-Chlorophenyl)-1-(tetrahydrofuran-3-ylmethyl)-1H-pyrazolo[4-
,3-c]pyridine; [0033]
3-(4-Chlorophenyl)-1-(1-ethylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridine;
[0034]
3-(4-Chlorophenyl)-1-(1-isopropylpiperidin-4-yl)-1H-pyrazolo[4,3-c-
]pyridine; [0035]
3-(4-Fluorophenyl)-1-(1-methylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridine;
[0036]
3-(4-Fluorophenyl)-1-piperidin-4-yl-1H-pyrazolo[4,3-c]pyridine;
[0037]
4-[1-(Tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl]ben-
zonitrile; and [0038]
4-[1-(1-Methylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl]benzonitrile-
.
[0039] Another object of the present invention is a compound of
formula (I) for use in therapy. The compounds as defined above are
useful as inhibitors of SSAO activity. As such, they are useful in
the treatment or prevention of conditions and diseases in which
inhibition of SSAO activity is beneficial. More specifically, they
are useful for the treatment or prevention of inflammation,
inflammatory diseases, immune or autoimmune disorders.
[0040] In particular, it is believed that compounds of formula (I)
are useful for the treatment or prevention of arthritis (such as
rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis
and psoriatic arthritis), synovitis, vasculitis, conditions
associated with inflammation of the bowel (such as Crohn's disease,
ulcerative colitis, inflammatory bowel disease and irritable bowel
syndrome), atherosclerosis, multiple sclerosis, Alzheimer's
disease, vascular dementia, pulmonary inflammatory diseases (such
as asthma, chronic obstructive pulmonary disease and acute
respiratory distress syndrome), fibrotic diseases (including
idiopathic pulmonary fibrosis, cardiac fibrosis and systemic
sclerosis (scleroderma)), inflammatory diseases of the skin (such
as contact dermatitis, atopic dermatitis and psoriasis), systemic
inflammatory response syndrome, sepsis, inflammatory and/or
autoimmune conditions of the liver (such as autoimmune hepatitis,
primary biliary cirrhosis, alcoholic liver disease, sclerosing
cholangitis, and autoimmune cholangitis), diabetes (type I or II)
and/or the complications thereof, chronic heart failure, congestive
heart failure, ischemic diseases (such as stroke and
ischemia-reperfusion injury), and myocardial infarction and/or the
complications thereof.
[0041] It is believed that the compounds of the invention are
especially useful for the treatment or prevention of vasculitis,
including, but not limited to, giant cell arteritis, Takayasu's
arteritis, Polyarteritis nodosa, Kawasaki disease, Wegener's
granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis,
Henoch-Schnlein purpura, cryoglobulinemia, cutaneous
leukocytoclastic angiitis and primary angiitis of the central
nervous system.
[0042] The invention thus includes the use of said compounds in the
manufacture of a medicament for the treatment or prevention of the
above-mentioned conditions and diseases. The invention also
includes methods for treatment or prevention of such conditions and
diseases, comprising administering to a mammal, including man, in
need of such treatment an effective amount of a compound as defined
above.
[0043] Methods delineated herein include those wherein the subject
is identified as in need of a particular stated treatment.
Identifying a subject in need of such treatment can be in the
judgment of a subject or a health care professional and can be
subjective (e.g. opinion) or objective (e.g. measurable by a test
or diagnostic method).
[0044] In other aspects, the methods herein include those further
comprising monitoring subject response to the treatment
administrations. Such monitoring may include periodic sampling of
subject tissue, fluids, specimens, cells, proteins, chemical
markers, genetic materials, etc. as markers or indicators of the
treatment regimen. In other methods, the subject is prescreened or
identified as in need of such treatment by assessment for a
relevant marker or indicator of suitability for such treatment.
[0045] In one embodiment, the invention provides a method of
monitoring treatment progress. The method includes the step of
determining a level of diagnostic marker (Marker) (e.g., any target
or cell type delineated herein modulated by a compound herein) or
diagnostic measurement (e.g., screen, assay) in a subject suffering
from or susceptible to a disorder or symptoms thereof delineated
herein, in which the subject has been administered a therapeutic
amount of a compound herein sufficient to treat the disease or
symptoms thereof. The level of Marker determined in the method can
be compared to known levels of Marker in either healthy normal
controls or in other afflicted patients to establish the subject's
disease status. In preferred embodiments, a second level of Marker
in the subject is determined at a time point later than the
determination of the first level, and the two levels are compared
to monitor the course of disease or the efficacy of the therapy. In
certain preferred embodiments, a pre-treatment level of Marker in
the subject is determined prior to beginning treatment according to
this invention; this pre-treatment level of Marker can then be
compared to the level of Marker in the subject after the treatment
commences, to determine the efficacy of the treatment.
[0046] In certain method embodiments, a level of Marker or Marker
activity in a subject is determined at least once. Comparison of
Marker levels, e.g., to another measurement of Marker level
obtained previously or subsequently from the same patient, another
patient, or a normal subject, may be useful in determining whether
therapy according to the invention is having the desired effect,
and thereby permitting adjustment of dosage levels as appropriate.
Determination of Marker levels may be performed using any suitable
sampling/expression assay method known in the art or described
herein. Preferably, a tissue or fluid sample is first removed from
a subject. Examples of suitable samples include blood, urine,
tissue, mouth or cheek cells, and hair samples containing roots.
Other suitable samples would be known to the person skilled in the
art. Determination of protein levels and/or mRNA levels (e.g.,
Marker levels) in the sample can be performed using any suitable
technique known in the art, including, but not limited to, enzyme
immunoassay, ELISA, radiolabeling/assay techniques,
blotting/chemiluminescence methods, real-time PCR, and the
like.
DEFINITIONS
[0047] The following definitions shall apply throughout the
specification and the appended claims.
[0048] Unless otherwise stated or indicated, the term
"C.sub.1-6-alkyl" denotes a straight or branched alkyl group having
from 1 to 6 carbon atoms. For parts of the range "C.sub.1-6-alkyl"
all subgroups thereof are contemplated such as C.sub.1-5-alkyl,
C.sub.1-4-alkyl, C.sub.1-3-alkyl, C.sub.1-2-alkyl, C.sub.2-6-alkyl,
C.sub.2-5-alkyl, C.sub.2-4-alkyl, C.sub.2-3-alkyl, C.sub.3-6-alkyl,
C.sub.4-5-alkyl, etc. Examples of said "C.sub.1-6-alkyl" include
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
t-butyl and straight- and branched-chain pentyl and hexyl.
[0049] Unless otherwise stated or indicated, the term
"halo-C.sub.1-6-alkyl" denotes a straight or branched
C.sub.1-6-alkyl group substituted by one or more halogen atoms.
Examples of said halo-C.sub.1-6-alkyl include 2-fluoroethyl,
fluoromethyl, trifluoromethyl and 2,2,2-trifluoroethyl.
[0050] Unless otherwise stated or indicated, the term
"hydroxy-C.sub.1-6-alkyl" denotes a straight or branched
C.sub.1-6-alkyl group that has a hydrogen atom thereof replaced
with OH. Examples of said hydroxy-C.sub.1-6-alkyl include
hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl and
2-hydroxy-2-methylpropyl.
[0051] Unless otherwise stated or indicated, the term
"cyano-C.sub.1-6-alkyl" denotes a straight or branched
C.sub.1-6-alkyl group that has a hydrogen atom thereof replaced
with cyano. Examples of said cyano-C.sub.1-6-alkyl include
cyanomethyl, 2-cyanoethyl, 2-cyanopropyl and
2-cyano-2-methylpropyl.
[0052] The derived expression "C.sub.1-6-alkoxy" is to be construed
accordingly where a C.sub.1-6-alkyl group is attached to the
remainder of the molecule through an oxygen atom. For parts of the
range "C.sub.1-6-alkoxy" all subgroups thereof are contemplated
such as C.sub.1-5-alkoxy, C.sub.1-4-alkoxy, C.sub.1-3-alkoxy,
C.sub.1-2-alkoxy, C.sub.2-6-alkoxy, C.sub.2-5-alkoxy,
C.sub.2-4-alkoxy, C.sub.2-3-alkoxy, C.sub.3-6-alkoxy,
C.sub.4-5-alkoxy, etc. Examples of said "C.sub.1-6-alkoxy" include
methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy,
sec-butoxy, t-butoxy and straight- and branched-chain pentoxy and
hexoxy etc.
[0053] Unless otherwise stated or indicated, the term
"C.sub.1-6-alkoxy-C.sub.1-6-alkyl" refers to a C.sub.1-6-alkoxy
group that is bonded to a C.sub.1-6-alkyl group via an oxygen atom
of said C.sub.1-6-alkoxy group. Representative examples of such
groups include methoxymethyl and ethoxyethyl. Unless otherwise
stated or indicated, the term "C.sub.1-6-acyl" denotes a carbonyl
group that is attached through its carbon atom to a hydrogen atom
(i.e., a formyl group) or to a straight or branched C.sub.1-5-alkyl
group, where alkyl is defined as above. For parts of the range
"C.sub.1-6-acyl" all subgroups thereof are contemplated such as
C.sub.1-5-acyl, C.sub.1-4-acyl, C.sub.1-3-acyl, C.sub.1-2-acyl,
C.sub.2-6-acyl, C.sub.2-5-acyl, C.sub.2-4-acyl, C.sub.2-3-acyl,
C.sub.3-6-acyl, C.sub.4-5-acyl, etc. Exemplary acyl groups include
formyl, acetyl, propanoyl, butanoyl, pentanoyl, hexanoyl.
[0054] Unless otherwise stated or indicated, the term
"C.sub.1-6-alkylsulfonyl" refers to a straight or branched
C.sub.1-6-alkyl group that is bonded to a sulfonyl group. Examples
of C.sub.1-6-alkyl-sulfonyl groups include methylsulfonyl and
ethylsulfonyl.
[0055] Unless otherwise stated or indicated, the term
"heterocyclyl" or "heterocyclic ring" refers to a fully saturated
or partially unsaturated, preferably fully saturated, monocyclic
ring system having 4 to 7 ring atoms with at least one heteroatom
such as O, N, or S, and the remaining ring atoms are carbon.
Examples of heterocyclic rings include piperidinyl,
tetrahydropyranyl, tetrahydrofuranyl, tetrahydrothienyl, azepinyl,
azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, morpholinyl,
imidazolinyl, imidazolidinyl, thiomorpholinyl, pyranyl, dioxanyl,
piperazinyl, homopiperazinyl and 5,6-dihydro-4H-1,3-oxazin-2-yl.
When present, the sulfur atom may be in an oxidized form (i.e.,
S.dbd.O or O.dbd.S.dbd.O). Exemplary heterocyclic groups containing
sulfur in oxidized form are 1,1-dioxido-thiomorpholinyl and
1,1-dioxido-isothiazolidinyl.
[0056] "Halogen" refers to fluorine, chlorine, bromine or
iodine.
[0057] "Hydroxy" refers to the OH radical.
[0058] "Cyano" refers to the CN radical.
[0059] "Optional" or "optionally" means that the subsequently
described event or circumstance may but need not occur, and that
the description includes instances where the event or circumstance
occurs and instances in which it does not.
[0060] "Pharmaceutically acceptable" means being useful in
preparing a pharmaceutical composition that is generally safe,
non-toxic and neither biologically nor otherwise undesirable and
includes being useful for veterinary use as well as human
pharmaceutical use.
[0061] "Treatment" as used herein includes prophylaxis of the named
disorder or condition, or amelioration or elimination of the
disorder once it has been established.
[0062] "An effective amount" refers to an amount of a compound that
confers a therapeutic effect on the treated subject. The
therapeutic effect may be objective (i.e., measurable by some test
or marker) or subjective (i.e., subject gives an indication of or
feels an effect).
[0063] "Prodrugs" refers to compounds that may be converted under
physiological conditions or by solvolysis to a biologically active
compound of the invention. A prodrug may be inactive when
administered to a subject in need thereof, but is converted in vivo
to an active compound of the invention. Prodrugs are typically
rapidly transformed in vivo to yield the parent compound of the
invention, e.g. by hydrolysis in the blood. The prodrug compound
usually offers advantages of solubility, tissue compatibility or
delayed release in a mammalian organism (see Silverman, R. B., The
Organic Chemistry of Drug Design and Drug Action, 2.sup.nd Ed.,
Elsevier Academic Press (2004), pp. 498-549). Prodrugs of a
compound of the invention may be prepared by modifying functional
groups, such as a hydroxy, amino or mercapto groups, present in a
compound of the invention in such a way that the modifications are
cleaved, either in routine manipulation or in vivo, to the parent
compound of the invention. Examples of prodrugs include, but are
not limited to, acetate, formate and succinate derivatives of
hydroxy functional groups or phenyl carbamate derivatives of amino
functional groups.
[0064] Throughout the specification and the appended claims, a
given chemical formula or name shall also encompass all salts,
hydrates, solvates, N-oxides and prodrug forms thereof. Further, a
given chemical formula or name shall encompass all tautomeric and
stereoisomeric forms thereof. Stereoisomers include enantiomers and
diastereomers. Enantiomers can be present in their pure forms, or
as racemic (equal) or unequal mixtures of two enantiomers.
Diastereomers can be present in their pure forms, or as mixtures of
diastereomers. Diastereomers also include geometrical isomers,
which can be present in their pure cis or trans forms or as
mixtures of those.
[0065] The compounds of formula (I) may be used as such or, where
appropriate, as pharmacologically acceptable salts (acid or base
addition salts) thereof. The pharmacologically acceptable addition
salts mentioned below are meant to comprise the therapeutically
active non-toxic acid and base addition salt forms that the
compounds are able to form. Compounds that have basic properties
can be converted to their pharmaceutically acceptable acid addition
salts by treating the base form with an appropriate acid. Exemplary
acids include inorganic acids, such as hydrogen chloride, hydrogen
bromide, hydrogen iodide, sulphuric acid, phosphoric acid; and
organic acids such as formic acid, acetic acid, propanoic acid,
hydroxyacetic acid, lactic acid, pyruvic acid, glycolic acid,
maleic acid, malonic acid, oxalic acid, benzenesulphonic acid,
toluenesulphonic acid, methanesulphonic acid, trifluoroacetic acid,
fumaric acid, succinic acid, malic acid, tartaric acid, citric
acid, salicylic acid, p-aminosalicylic acid, pamoic acid, benzoic
acid, ascorbic acid and the like. Exemplary base addition salt
forms are the sodium, potassium, calcium salts, and salts with
pharmaceutically acceptable amines such as, for example, ammonia,
alkylamines, benzathine, and amino acids, such as, e.g. arginine
and lysine. The term addition salt as used herein also comprises
solvates which the compounds and salts thereof are able to form,
such as, for example, hydrates, alcoholates and the like.
Compositions
[0066] For clinical use, the compounds of the invention are
formulated into pharmaceutical formulations for various modes of
administration. It will be appreciated that compounds of the
invention may be administered together with a physiologically
acceptable carrier, excipient, or diluent. The pharmaceutical
compositions of the invention may be administered by any suitable
route, preferably by oral, rectal, nasal, topical (including buccal
and sublingual), sublingual, transdermal, intrathecal, transmucosal
or parenteral (including subcutaneous, intramuscular, intravenous
and intradermal) administration.
[0067] Other formulations may conveniently be presented in unit
dosage form, e.g., tablets and sustained release capsules, and in
liposomes, and may be prepared by any methods well known in the art
of pharmacy. Pharmaceutical formulations are usually prepared by
mixing the active substance, or a pharmaceutically acceptable salt
thereof, with conventional pharmaceutically acceptable carriers,
diluents or excipients. Examples of excipients are water, gelatin,
gum arabicum, lactose, microcrystalline cellulose, starch, sodium
starch glycolate, calcium hydrogen phosphate, magnesium stearate,
talcum, colloidal silicon dioxide, and the like. Such formulations
may also contain other pharmacologically active agents, and
conventional additives, such as stabilizers, wetting agents,
emulsifiers, flavouring agents, buffers, and the like. Usually, the
amount of active compounds is between 0.1-95% by weight of the
preparation, preferably between 0.2-20% by weight in preparations
for parenteral use and more preferably between 1-50% by weight in
preparations for oral administration.
[0068] The formulations can be further prepared by known methods
such as granulation, compression, microencapsulation, spray
coating, etc. The formulations may be prepared by conventional
methods in the dosage form of tablets, capsules, granules, powders,
syrups, suspensions, suppositories or injections. Liquid
formulations may be prepared by dissolving or suspending the active
substance in water or other suitable vehicles. Tablets and granules
may be coated in a conventional manner. To maintain therapeutically
effective plasma concentrations for extended periods of time,
compounds of the invention may be incorporated into slow release
formulations.
[0069] The dose level and frequency of dosage of the specific
compound will vary depending on a variety of factors including the
potency of the specific compound employed, the metabolic stability
and length of action of that compound, the patient's age, body
weight, general health, sex, diet, mode and time of administration,
rate of excretion, drug combination, the severity of the condition
to be treated, and the patient undergoing therapy. The daily dosage
may, for example, range from about 0.001 mg to about 100 mg per
kilo of body weight, administered singly or multiply in doses, e.g.
from about 0.01 mg to about 25 mg each. Normally, such a dosage is
given orally but parenteral administration may also be chosen.
Preparation of Compounds of the Invention
[0070] The compounds of formula (I) above may be prepared by, or in
analogy with, conventional methods. The preparation of
intermediates and compounds according to the examples of the
present invention may in particular be illuminated by the following
Scheme. Definitions of variables in the structures in schemes
herein are commensurate with those of corresponding positions in
the formulae delineated herein.
##STR00005##
wherein LG is a leaving group; and R.sup.1, R.sup.2 and a are as
defined in formula (I).
[0071] Compounds of formula (I) may easily be synthesised by
hydroxyalkylation of 4-chloropyridine with the appropriate
benzaldehyde (II) to give an aryl-(4-chloro-pyridin-3-yl)-methanol
derivative (III). Subsequent oxidation of the alcohol results in
the corresponding aryl-(4-chloro-pyridin-3-yl)-methanone derivative
(IV). Formation of the pyrazolo[4,3-c]pyridine ring system is
accomplished by condensation of (IV) with hydrazine to give the
3-aryl-pyrazolo[4,3-c]pyridine intermediate (V). In the last step,
the intermediate (V) is alkylated to install the appropriate
heterocyclyl or heterocyclyl-alkyl group in the compound of formula
(I). A compound of formula (I) can optionally be transformed into
another compound of formula (I).
[0072] The necessary starting materials for preparing the compounds
of formula (I) are either commercially available, or may be
prepared by methods known in the art.
[0073] The processes described below in the experimental section
may be carried out to give a compound of the invention in the form
of a free base or as an acid addition salt. A pharmaceutically
acceptable acid addition salt may be obtained by dissolving the
free base in a suitable organic solvent and treating the solution
with an acid, in accordance with conventional procedures for
preparing acid addition salts from base compounds. Examples of
addition salt forming acids are mentioned above.
[0074] The compounds of formula (I) may possess one or more chiral
carbon atoms, and they may therefore be obtained in the form of
optical isomers, e.g., as a pure enantiomer, or as a mixture of
enantiomers (racemate) or as a mixture containing diastereomers.
The separation of mixtures of optical isomers to obtain pure
enantiomers is well known in the art and may, for example, be
achieved by fractional crystallization of salts with optically
active (chiral) acids or by chromatographic separation on chiral
columns.
[0075] The chemicals used in the synthetic routes delineated herein
may include, for example, solvents, reagents, catalysts, and
protecting group and deprotecting group reagents. Examples of
protecting groups are t-butoxycarbonyl (Boc), benzyl and trityl
(triphenylmethyl). The methods described above may also
additionally include steps, either before or after the steps
described specifically herein, to add or remove suitable protecting
groups in order to ultimately allow synthesis of the compounds. In
addition, various synthetic steps may be performed in an alternate
sequence or order to give the desired compounds. Synthetic
chemistry transformations and protecting group methodologies
(protection and deprotection) useful in synthesizing applicable
compounds are known in the art and include, for example, those
described in R. Larock, Comprehensive Organic Transformations, VCH
Publishers (1989); T. W. Greene and P. G. M. Wuts, Protective
Groups in Organic Synthesis, 3.sup.rd Ed., John Wiley and Sons
(1999); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for
Organic Synthesis, John Wiley and Sons (1994); and L. Paquette,
ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and
Sons (1995) and subsequent editions thereof.
[0076] The following abbreviations have been used: [0077] Ac
Acetate [0078] Aq Aqueous [0079] Boc tert-Butoxycarbonyl [0080]
Calcd Calculated [0081] Cbz Carboxybenzyloxy [0082] d Day [0083]
DCM Dichloromethane [0084] DIAD Diisopropyl azodicarboxylate [0085]
DIPEA Diisopropylethylamine [0086] DMF N,N'-Dimethylformamide
[0087] ES.sup.+ Electrospray [0088] h Hour(s) [0089] HPLC High
performance liquid chromatography [0090] HRMS High resolution mass
spectrometry [0091] IR Infrared [0092] LCMS Liquid chromatography
mass spectrometry [0093] M Molar [0094] [MH.sup.+] Protonated
molecular ion [0095] min Minutes [0096] NMR Nuclear Magnetic
resonance [0097] RP Reverse phase [0098] R.sub.T Retention time
[0099] MS Mass spectrometry [0100] sat Saturated [0101] sec Seconds
[0102] THF Tetrahydrofuran [0103] TFA Trifluoroacetic acid [0104]
TMS Tetramethylsilane
[0105] The recitation of a listing of chemical groups in any
definition of a variable herein includes definitions of that
variable as any single group or combination of listed groups. The
recitation of an embodiment herein includes that embodiment as any
single embodiment or in combination with any other embodiments or
portions thereof.
[0106] The invention will now be further illustrated by the
following non-limiting examples. The specific examples below are to
be construed as merely illustrative, and not limitative of the
remainder of the disclosure in any way whatsoever. Without further
elaboration, it is believed that one skilled in the art can, based
on the description herein, utilize the present invention to its
fullest extent. All references and publications cited herein are
hereby incorporated by reference in their entirety.
EXAMPLES AND INTERMEDIATE COMPOUNDS
Experimental Methods
[0107] All reagents were commercial grade and were used as received
without further purification, unless otherwise specified. Reagent
grade solvents were used in all cases. Analytical LCMS was
performed on a Waters ZQ mass spectrometer connected to an Agilent
1100 HPLC system. Analytical HPLC was performed on an Agilent 1100
system. High-resolution mass spectra (HRMS) were obtained on an
Agilent MSD-TOF connected to an Agilent 1100 HPLC system. During
the analyses the calibration was checked by two masses and
automatically corrected when needed. Spectra are acquired in
positive electrospray mode. The acquired mass range was m/z
100-1100. Profile detection of the mass peaks was used. Flash
chromatography was performed on either a Flash Master Personal
system equipped with Strata SI-1 silica gigatubes or by gravity
flash chromatography using Apollo Scientific silica gel (40-63
.mu.m, 60 .ANG.). Reverse Phase HPLC was performed on a Gilson
system (Gilson 322 pump with Gilson 321 equilibration pump and
Gilson 215 autosampler) equipped with YMC ODS-A 100/150.times.20 mm
columns. Preparative LCMS was performed on a Waters system
(2.times. Gemini, X18, 110 .ANG., 50.times.21.2 mm, 5 nm).
Microwave irradiations were carried out using a Biotage microwave.
The compounds were automatically named using ACD 6.0.
[0108] Analytical HPLC and LCMS data were obtained with:
System A: Phenomenex Synergi Hydro RP (C18, 30.times.4.6 mm, 4 nm),
gradient 5-100% CH.sub.3CN (+0.085% TFA) in water (+0.1% TFA), 1.5
mL/min, gradient time 1.75 min, 200 nm, 30.degree. C.; or System B:
Phenomenex Synergi Hydro RP (C18, 150.times.4.6 mm, 4 nm), gradient
5-100% CH.sub.3CN (+0.085% TFA) in water (+0.1% TFA), 1.5 mL/min,
gradient time 7 min, 200 nm, 30.degree. C.; or System C: Phenomenex
Synergi Hydro RP-80A (C18, 150.times.4.6 mm, 4 nm), gradient 5-95%
CH.sub.3CN (+0.1% HCO.sub.2H) in water (+0.1% HCO.sub.2H), 1
mL/min, gradient time 15.5 min, 200-300 nm, 40.degree. C.
Intermediate 1
3-(4-Chlorophenyl)-1H-pyrazolo[4,3-c]pyridine
##STR00006##
[0110] Diisopropylamine (11.7 mL, 83.3 mmol) was dissolved in THF
(200 mL) under a nitrogen atmosphere at 0.degree. C. and
n-butyllithium (52.5 mL, 1.6 M in hexanes, 84.0 mmol) was added.
The solution was stirred for 1 h, cooled to -78.degree. C. and
4-chloropyridine hydrochloride (5.00 g, 33.3 mmol) was added
portionwise. The reaction mixture was stirred 2 h and
4-chlorobenzaldehyde (4.68 g, 33.3 mmol) was added. The reaction
mixture was allowed to warm slowly to room temperature and stirred
for 3 d. Sat aq NH.sub.4Cl solution (20 mL) was iii added and the
reaction mixture was poured into 1 M aq Na.sub.2CO.sub.3 solution
(500 mL). The layers were separated and the aq layer was extracted
with DCM (2.times.500 mL). The combined organic layers were dried
(MgSO.sub.4) and the solvents were removed in vacuo to give
(4-chlorophenyl)-(4-chloro-pyridin-3-yl)-methanol (7.57 g, 89.4%)
as a light brown solid.
[0111] Analytical HPLC: purity 77% (System B, R.sub.T=4.55 min);
Analytical LCMS: purity>90% (System A, R.sub.T=1.66 min),
ES.sup.+: 254.0 [.sup.35ClMH].sup.+ and 256.0
[.sup.37ClMH].sup.+.
[0112] (4-Chlorophenyl)-(4-chloro-pyridin-3-yl)-methanol (7.57 g,
29.8 mmol) was dissolved in dry acetone (150 mL) and chromium (VI)
oxide (8.94 g, 89.4 mmol) was added. The reaction mixture was
stirred for 18 h and then poured into sat aq NaHCO.sub.3 solution
(500 mL) and extracted with DCM (2.times.500 mL). The combined
organic layers were dried (MgSO.sub.4) and the solvents were
removed in vacuo. The residue was purified by column chromatography
(normal phase, 50 g, Strata SI-1, silica gigatube, DCM (600 mL)) to
give (4-chlorophenyl)-(4-chloropyridin-3-yl)-methanone (4.88 g,
65.0%) as a yellow oil.
[0113] Analytical LCMS: purity 100% (System A, R.sub.T=2.14 min),
ES.sup.+: 252.0 [.sup.35ClMH].sup.+ and 254.0
[.sup.37ClMH].sup.+.
[0114] (4-Chlorophenyl)-(4-chloropyridin-3-yl)-methanone (3.88 g,
15.4 mmol) was dissolved in MeOH (20 mL) at room temperature and
hydrazine hydrate (20 mL) was added. The reaction mixture was
stirred for 3 h. The precipitate was filtered and purified by
recrystallisation from PhMe/MeOH (.about.4:1, .about.150 mL) to
give 3-(4-chlorophenyl)-1H-pyrazolo[4,3-c]pyridine (1.16 g, 33.0%)
as a yellow solid.
[0115] Analytical HPLC: purity 99.2% (System B, R.sub.T=4.29 min);
Analytical LCMS: purity 94.8% (System B, R.sub.T=4.69 min),
ES.sup.+: 230.0 [.sup.35ClMH].sup.+ and 232.1
[.sup.37ClMH].sup.+.
Intermediate 2
3-(4-Fluorophenyl)-1H-pyrazolo[4,3-c]pyridine
##STR00007##
[0117] 3-(4-Fluorophenyl)-1H-pyrazolo[4,3-c]pyridine was prepared
according to the method used for the preparation of Intermediate 1,
but using 4-fluorobenzaldehyde instead of 4-chlorobenzaldehyde.
Excess MnO.sub.2 was used instead of CrO.sub.3 in the oxidation
step. The title compound was obtained as a yellow solid (791 mg,
55.8% overall yield, 3 steps).
[0118] Analytical HPLC: purity 95.3% (System B, R.sub.T=3.97 min);
Analytical LCMS: purity>90% (System A, R.sub.T=1.38 min),
ES.sup.+: 214.4 [MH].sup.+.
Intermediate 3
3-(4-Methylphenyl)-1H-pyrazolo[4,3-c]pyridine
##STR00008##
[0120] 3-(4-Methylphenyl)-1H-pyrazolo[4,3-c]pyridine was prepared
according to the method used for the preparation of Intermediate 1,
but using 4-methylbenzaldehyde instead of 4-chlorobenzaldehyde.
Excess MnO.sub.2 was used instead of CrO.sub.3 in the oxidation
step. The title compound was obtained as an off-white solid (2.05
g, 16% overall yield, 3 steps). Analytical LCMS: purity 100%
(System C, R.sub.T=3.26 min), ES.sup.+: 210 [MH]+.
Intermediate 4
4-(1H-Pyrazolo[4,3-c]pyridin-3-yl)-benzonitrile
##STR00009##
[0122] 4-(1H-Pyrazolo[4,3-c]pyridin-3-yl)-benzonitrile was prepared
according to the method used for the preparation of Intermediate 1,
but using 4-formyl-benzonitrile instead of 4-chlorobenzaldehyde.
The title compound was obtained as a white solid (846 mg, 28.8%
overall yield, 3 steps).
[0123] Analytical HPLC: purity 95.8% (System B, R.sub.T=3.76 min);
Analytical LCMS: purity>90% (System A, R.sub.T=1.38 min),
ES.sup.+: 221.4 [MH].sup.+.
Example 1
3-(4-Fluorophenyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[4,3-c]pyridine
##STR00010##
[0125] Intermediate 2 (200 mg, 0.94 mmol) and triphenylphosphine
(369 mg, 1.41 mmol) were suspended in DCM (5 mL) and
4-hydroxytetrahydropyran (134 .mu.L, 1.41 mmol) was added, followed
by DIAD (277 .mu.L, 1.41 mmol). The reaction mixture was stirred
for 3 d. The solvent was removed in vacuo to give a yellow gum. The
residue was purified by reverse phase HPLC (YMC ODS-A 100.times.20
mm, 5 .mu.m, 25 mL/min, gradient 60% to 100% (over 7 min) then 100%
(3 min) MeOH in 10% MeOH/water) to give
3-(4-fluorophenyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[4,3-c]pyridin-
e (29 mg, 10.4%) as a white solid.
[0126] Analytical HPLC: purity 99.6% (System B, R.sub.T=4.67 min);
Analytical LCMS: purity 100% (System B, R.sub.T=4.61 min),
ES.sup.+: 298.5 [MH].sup.+; HRMS calcd for
C.sub.17H.sub.16FN.sub.3O: 297.1277. found 297.1284.
Example 2
3-(4-Chlorophenyl)-2-(tetrahydro-2H-pyran-4-yl)-2H-pyrazolo[4,3-c]pyridine
##STR00011##
[0128] Intermediate 1 (100 mg, 0.44 mmol) and triphenylphosphine
(129 mg, 0.49 mmol) were suspended in DCM (2 mL) and
4-hydroxytetrahydropyran (43.0 .mu.L, 0.45 mmol) and DIAD (97.0
.mu.L, 0.49 mmol) were added. The reaction mixture was stirred for
5 d. The solvents were removed in vacuo and the residue was
purified by reverse phase HPLC (YMC ODS-A 100.times.20 mm, 5 .mu.m,
25 mL/min, gradient 40% to 100% (over 7 min) then 100% (3 min) MeOH
in 10% MeOH/water) to give
3-(4-chlorophenyl)-2-(tetrahydro-2H-pyran-4-yl)-2H-pyrazolo[4,3-c]pyridin-
e (11 mg, 7.8%) as a white solid.
[0129] Analytical HPLC: purity 99.5% (System B, R.sub.T=4.97 min);
Analytical LCMS: purity 100% (System B, R.sub.T=5.34 min),
ES.sup.+: 314.0 [.sup.35ClMH].sup.+ and 316.0 [.sup.37ClMH].sup.+;
HRMS calcd for C.sub.17H.sub.16ClN.sub.3O: 313.0982. found
313.0980.
Example 3
3-(4-Methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[4,3-c]pyridine
##STR00012##
[0131] 4-Hydroxytetrahydropyran (4.86 g, 47.6 mmol) was dissolved
in DCM (40 mL) and triethylamine (6.95 mL, 49.9 mmol). The reaction
mixture was cooled to 0.degree. C. and a solution of
methanesulfonyl chloride (5.72 g, 49.9 mmol) in DCM (10 mL) was
added dropwise. The reaction mixture was stirred at 0.degree. C.
for 5 min and then allowed to warm to room temperature and stirred
for 20 h. The solvents were removed in vacuo to give a white
residue which was partitioned between EtOAc and H.sub.2O. The aq
phase was extracted with EtOAc (2.times.100 mL). The organic layers
were combined, dried (MgSO.sub.4) and the solvents were removed in
vacuo to give tetrahydro-2H-pyran-4-yl methanesulfonate (8.53 g,
99%) as a colourless gum which solidified on standing.
[0132] Intermediate 3 (0.40 g, 1.91 mmol), tetrahydro-2H-pyran-4-yl
methanesulfonate (1.03 g, 5.72 mmol) and K.sub.2CO.sub.3 (0.52 g,
3.76 mmol) were dissolved in MeCN (7 mL) and the reaction mixture
was heated under reflux for 50 h. The solvents were removed in
vacuo. The resulting residue was partitioned between EtOAc (25 mL)
and H.sub.2O (25 mL). The aqueous phase was extracted with EtOAc
(2.times.100 mL). The organic layers were combined, dried
(MgSO.sub.4) and the solvents were removed in vacuo. The residue
was purified by Waters Preparative LC-MS (2.times. Gemini, X18, 110
.ANG., 50.times.21.2 mm, 5 .mu.m, 20 mL/min, 25.degree. C.,
gradient 5% (held for 0.6 min) to 100% (over 10 min), MeCN in
H.sub.2O (0.1% formic acid), 200-800 nm) to give
3-(4-methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[4,3-c]pyridin-
e (103 mg, 18.6%) as an off-white solid.
[0133] Analytical HPLC: purity 99.0% (System B, R.sub.T=9.02 min);
Analytical LCMS: purity 100% (System B, R.sub.T=8.39 min),
ES.sup.+: 294.6 [MH].sup.+; HRMS calcd for
C.sub.18H.sub.19N.sub.3O: 293.1528. found 293.1528.
Example 4
3-(4-Chlorophenyl)-1-[(3R)-tetrahydrofuran-3-yl]-1H-pyrazolo[4,3-c]pyridin-
e
##STR00013##
[0135] Intermediate 1 (200 mg, 0.87 mmol) and triphenylphosphine
(342 mg, 1.31 mmol) were suspended in DCM (5 mL) and
(S)-3-hydroxy-tetrahydrofuran (89.0 .mu.L, 1.31 mmol) was added,
followed by DIAD (257 .mu.L, 1.31 mmol). The reaction mixture was
stirred at room temperature for 48 h. The solvents were removed in
vacuo. The residue was purified by reverse phase HPLC (YMC ODS-A
100.times.20 mm, 5 .mu.m, 25 mL/min, gradient 60% to 100% (over 7
min) then 100% (3 min) MeOH in 10% MeOH/water) to give
3-(4-chlorophenyl)-1-[(3R)-tetrahydrofuran-3-yl]-1H-pyrazolo[4,3-c]pyridi-
ne (153 mg, 58.6%) as a light yellow gum.
[0136] Analytical HPLC: purity 100% (System B, R.sub.T=4.78 min);
Analytical LCMS: purity 100% (System B, R.sub.T=4.88 min),
ES.sup.+: 300.5 [.sup.35ClMH].sup.+ and 302.5 [.sup.37ClMH].sup.+;
HRMS calcd for C.sub.16H.sub.14ClN.sub.3O: 299.0825. found
299.0831.
Example 5
3-(4-Chlorophenyl)-1-piperidin-4-yl-1H-pyrazolo[4,3-c]pyridine
##STR00014##
[0138] Polymer-bound triphenylphosphine (1.81 g, 3 mmol/g, 5.44
mmol) was suspended in DCM (10 mL) and stirred for 30 min. DIAD
(1.07 mL, 5.44 mmol), 1-Boc-4-hydroxypiperidine (1.09 g, 5.44 mmol)
and Intermediate 1 (500 mg, 2.18 mmol) were added. The reaction
mixture was stirred at room temperature for 18 h. The reaction
mixture was filtered and the filtrate concentrated in vacuo. The
residue was purified by reverse phase HPLC (YMC ODS-A 100.times.20
mm, 5 .mu.m, 25 mL/min, gradient 40% to 100% (over 7 min) then 100%
(3 min) MeOH in 10% MeOH/water) to give
4-[3-(4-chlorophenyl)-pyrazolo[4,3-c]pyridin-1-yl]-piperidine-1-carboxyli-
c acid tert-butyl ester (200 mg, 22.2%) as a light yellow gum.
[0139] Analytical HPLC: purity 100% (System B, R.sub.T=6.13 min);
Analytical LCMS: purity>90% (System A, R.sub.T=2.09 min),
ES.sup.+: 412.9 [.sup.35ClMH].sup.+ and 415.0
[.sup.37ClMH].sup.+.
[0140]
4-[3-(4-Chlorophenyl)-pyrazolo[4,3-c]pyridin-1-yl]-piperidine-1-car-
boxylic acid tert-butyl ester (200 mg, 0.48 mmol) was dissolved in
DCM (5 mL) and TFA (5 mL) was added. The reaction mixture was
stirred at room temperature for 30 min. The solvents were removed
in vacuo and the residue was dissolved in 1 M aq Na.sub.2CO.sub.3
solution (50 mL) and extracted with DCM (3.times.50 mL). The
combined organic layers were dried (MgSO.sub.4) and the solvents
removed in vacuo. The residue was purified by reverse phase HPLC
(YMC ODS-A 100.times.20 mm, 5 .mu.m, 25 mL/min, gradient 40% to
100% (over 7 min) then 100% (3 min) MeOH in 10% MeOH/water) to give
3-(4-chlorophenyl)-1-piperidin-4-yl-1H-pyrazolo[4,3-c]-pyridine (76
mg, 50.2%) as a white solid.
[0141] Analytical HPLC: purity 100% (System B, R.sub.T=3.74 min);
Analytical LCMS: purity 100% (System B, R.sub.T=3.60 min),
ES.sup.+: 313.1 [.sup.35ClMH].sup.+ and 315.0 [.sup.37ClMH].sup.+;
HRMS calcd for C.sub.17H.sub.17ClN.sub.4: 312.1142. found
312.1141.
Example 6
3-(4-Chlorophenyl)-1-(1-methylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridine
##STR00015##
[0143] Polymer-bound triphenylphosphine (670 mg, 3 mmol/g, 2.00
mmol) was suspended in DCM (5 mL) and stirred for 30 min. DIAD (396
.mu.L, 2.01 mmol), 4-hydroxy-N-methyl-piperidine (232 mg, 2.01
mmol) and Intermediate 1 (185 mg, 0.81 mmol) were added. The
reaction mixture was stirred for 18 h. The reaction mixture was
filtered and the filtrate concentrated in vacuo. The residue was
purified by reverse phase HPLC (YMC ODS-A 100.times.20 mm, 5 .mu.m,
25 mL/min, gradient 60% to 100% (over 7 min) then 100% (3 min) MeOH
in 10% MeOH/water), then by reverse phase HPLC (YMC ODS-A
150.times.20 mm, 5 .mu.m, 15 mL/min, gradient 0% to 40% (over 12
min) then 100% (3 min) MeOH in water (1% formic acid)). The residue
was de-salted using K.sub.2CO.sub.3 in DCM to give
3-(4-chlorophenyl)-1-(1-methylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridine
(31 mg, 11.8%) as a white solid.
[0144] Analytical HPLC: purity 100% (System B, R.sub.T=3.77 min);
Analytical LCMS: purity 100% (System B, R.sub.T=4.16 min),
ES.sup.+: 327.0 [.sup.35ClMH].sup.+ and 329.0 [.sup.37ClMH].sup.+;
HRMS calcd for C.sub.18H.sub.19ClN.sub.4: 326.1298. found
326.1303.
Example 7
{4-[3-(4-Chlorophenyl)-1H-pyrazolo[4,3-c]pyridin-1-yl]piperidin-1-yl}aceto-
nitrile
##STR00016##
[0146] Example 5 (185 mg, 0.59 mmol) was dissolved in DMF (5 mL)
and DIPEA (91.6 mg, 123 .mu.L, 0.71 mmol) and iodoacetonitrile
(51.0 .mu.L, 0.71 mmol) were added. The reaction mixture was heated
using a Biotage microwave (100.degree. C., absorption high,
pre-stirring 30 sec) for 10 min, and then concentrated in vacuo.
The residue was dissolved in MeOH (5 mL), poured into 1 M aq
Na.sub.2CO.sub.3 solution (50 mL) and extracted with EtOAc
(3.times.50 mL). The combined organic layers were dried
(MgSO.sub.4) and concentrated in vacuo. The residue was purified by
reverse phase HPLC (YMC ODS-A 100.times.20 mm, 5 .mu.m, 25 mL/min,
gradient 60% to 100% (over 7 min) then 100% (3 min) MeOH in 10%
MeOH/water) to give
{4-[3-(4-chlorophenyl)-1H-pyrazolo[4,3-c]pyridin-1-yl]piperidin-1-yl}acet-
onitrile (86 mg, 41.4%) as a cream solid.
[0147] Analytical HPLC: purity 97.9% (System B, R.sub.T=4.57 min);
Analytical LCMS: purity 100% (System B, R.sub.T=4.61 min),
ES.sup.+: 352.5 [.sup.35ClMH].sup.+ and 354.5 [.sup.37ClMH].sup.+;
HRMS calcd for C.sub.19H.sub.18ClN.sub.5: 351.1251. found
351.1246
Example 8
3-(4-Chlorophenyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazolo[4,3-c]py-
ridine
##STR00017##
[0149] Sodium hydride (52 mg, 60% dispersion in mineral oil, 1.31
mmol) was suspended in THF (3 mL) and Intermediate 1 (200 mg, 0.87
mmol) and 4-bromomethyltetrahydropyran (187 mg, 1.04 mmol) were
added. The reaction mixture was heated using a Biotage microwave
(100.degree. C., absorption normal, pre-stirring 15 sec) for 1 h,
then at 120.degree. C. for 1 h and at 125.degree. C. for 30 min,
and then concentrated in vacuo. The residue was poured into 1 M aq
Na.sub.2CO.sub.3 solution (50 mL) and extracted with DCM
(3.times.50 mL). The combined organic layers were dried
(MgSO.sub.4) and concentrated in vacuo. The residue was purified by
reverse phase HPLC (YMC ODS-A 100.times.20 mm, 5 .mu.m, 25 mL/min,
gradient 60% to 100% (over 7 min) then 100% (3 min) MeOH in 10%
MeOH/water and YMC ODS-A 150.times.20 mm, 5 .mu.m, 15 mL/min,
gradient 4% to 100% (over 12 min) then 100% (3 min) MeOH+1% formic
acid in water+1% formic acid). The residue was de-salted using
K.sub.2CO.sub.3 in DCM to give
3-(4-chlorophenyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazolo[4,-
3-c]pyridine as a yellow gum (106 mg, 0.33 mmol, 37.1%).
[0150] Analytical HPLC: purity 100% (System B, R.sub.T=4.99 min);
Analytical LCMS: purity 100% (System B, R.sub.T=5.38 min),
ES.sup.+: 328.0 [.sup.35ClMH].sup.+ and 330.0 [.sup.37ClMH].sup.+;
HRMS calcd for C.sub.18H.sub.18ClN.sub.3O: 327.1138. found
327.1149.
Example 9
3-(4-Chlorophenyl)-1-[1-(methylsulfonyl)piperidin-4-yl]-1H-pyrazolo[4,3-c]-
pyridine
##STR00018##
[0152] Example 5 (123 mg, 0.39 mmol) was dissolved in DCM (5 mL)
and DIPEA (75 .mu.L, 0.43 mmol) and methanesulfonyl chloride (33.5
.mu.L, 0.43 mmol) were added. The reaction mixture was stirred for
2 h, diluted with DCM (50 mL), washed with 1 M aq Na.sub.2CO.sub.3
solution (50 mL) and the organic layer was dried (MgSO.sub.4) and
concentrated in vacuo. The residue was purified by reverse phase
HPLC (YMC ODS-A 100.times.20 mm, 5 .mu.m, 25 mL/min, gradient 40%
to 100% (over 7 min) then 100% (3 min) MeOH in 10% MeOH/water) to
give
3-(4-chlorophenyl)-1-[1-(methylsulfonyl)piperidin-4-yl]-1H-pyrazolo[4,3-c-
]pyridine (61 mg, 39.7%) as a white solid.
[0153] Analytical HPLC: purity 100% (System B, R.sub.T=4.98 min);
Analytical LCMS: purity 100% (System B, R.sub.T=5.03 min),
ES.sup.+: 391.5 [.sup.35ClMH].sup.+ and 393.6 [.sup.37ClMH].sup.+;
HRMS calcd for C.sub.18H.sub.19ClN.sub.4O.sub.2S: 390.0917. found
390.0926.
Example 10
1-(1-Acetylpiperidin-4-yl)-3-(4-chlorophenyl)-1H-pyrazolo[4,3-c]pyridine
##STR00019##
[0155] Example 5 (167 mg, 0.53 mmol) was dissolved in DCM (5 mL)
and DIPEA (102 .mu.L, 0.59 mmol) and acetyl chloride (41.5 .mu.L,
0.59 mmol) were added. The reaction mixture was stirred for 2 h,
diluted with DCM (50 mL), washed with 1 M aq Na.sub.2CO.sub.3
solution (50 mL) and the organic layer was dried (MgSO.sub.4) and
concentrated in vacuo. The residue was purified by reverse phase
HPLC (YMC ODS-A 100.times.20 mm, 5 .mu.m, 25 mL/min, gradient 60%
to 100% (over 7 min) then 100% (3 min) MeOH in 10% MeOH/water),
dissolved in EtOAc (50 mL), washed with 1 M aqueous HCl (50 mL),
dried (MgSO.sub.4) and concentrated in vacuo to give
1-(1-acetylpiperidin-4-yl)-3-(4-chlorophenyl)-1H-pyrazolo[4,3-c]pyridine
(35 mg, 18.6%) as a white solid.
[0156] Analytical HPLC: purity 100% (System B, R.sub.T=4.62 min);
Analytical LCMS: purity 100% (System B, R.sub.T=4.70 min),
ES.sup.+: 355.6 [.sup.35ClMH].sup.+ and 357.5 [.sup.37ClMH].sup.+;
HRMS calcd for C.sub.19H.sub.19ClN.sub.4O: 354.1247. found
354.1263.
Example 11
3-(4-Chlorophenyl)-1-[1-(2-methoxyethyl)piperidin-4-yl]-1H-pyrazolo[4,3-c]-
pyridine
##STR00020##
[0158] Example 5 (162 mg, 0.52 mmol) was dissolved in DMF (5 mL)
and DIPEA (108 .mu.L, 0.62 mmol) and (2-bromoethyl)methyl ether (58
.mu.L, 0.62 mmol) were added. The reaction mixture was heated using
a Biotage microwave (100.degree. C., absorption high, pre-stirring
30 sec) for 10 min and at 120.degree. C. for 10 min, and then
concentrated in vacuo. The residue was dissolved in MeOH (5 mL),
poured into 1 M aq Na.sub.2CO.sub.3 solution (50 mL) and extracted
with EtOAc (3.times.50 mL). The combined organic layers were dried
(MgSO.sub.4) and concentrated in vacuo. The residue was purified by
reverse phase HPLC (YMC ODS-A 100.times.20 mm, 5 .mu.m, 25 mL/min,
gradient 60% to 100% (over 7 min) then 100% (3 min) MeOH in 10%
MeOH/water and YMC ODS-A 100.times.20 mm, 5 .mu.m, 25 mL/min,
gradient 60% to 90% (over 7 min) then 100% (3 min) MeOH in 10%
MeOH/water) to give
3-(4-chlorophenyl)-1-[1-(2-methoxyethyl)piperidin-4-yl]-1H-pyrazolo[4,3-c-
]pyridine (29 mg, 15.0%) as a colourless gum.
[0159] Analytical HPLC: purity 99.8% (System B, R.sub.T=3.96 min);
Analytical LCMS: purity 100% (System B, R.sub.T=4.01 min),
ES.sup.+: 371.6 [.sup.35ClMH].sup.+ and 373.5 [.sup.37ClMH].sup.+;
HRMS calcd for C.sub.20H.sub.23ClN.sub.4O: 370.1560. found
370.1575.
Example 12
3-(4-Chlorophenyl)-1-piperidin-3-yl-1H-pyrazolo[4,3-c]pyridine
##STR00021##
[0161] Intermediate 1 (200 mg, 0.87 mmol) and triphenylphosphine
(342 mg, 1.31 mmol) were suspended in DCM (5 mL) and
1-Boc-3-hydroxypiperidine (263 mg, 1.31 mmol) and DIAD (257 .mu.L,
1.31 mmol) were added. The reaction mixture was stirred for 3 h and
TFA (3 mL) was added. The reaction mixture was stirred for 1 h and
concentrated in vacuo. The residue was dissolved in 1 M aq HCl (50
mL) and washed with DCM (2.times.30 mL). The aq layer was basified
with NaOH and extracted with DCM (3.times.50 mL). The combined
organic extracts were dried (MgSO.sub.4) and concentrated in vacuo.
The residue was purified by reverse phase HPLC (YMC ODS-A
100.times.20 mm, 5 .mu.m, 25 mL/min, gradient 60% to 100% (over 7
min) then 100% (3 min) MeOH in 10% MeOH/water) to give
3-(4-chlorophenyl)-1-piperidin-3-yl-1H-pyrazolo[4,3-c]pyridine (41
mg, 15.1%) as a white solid.
[0162] Analytical HPLC: purity 98.2% (System B, R.sub.T=3.85 min);
Analytical LCMS: purity 100% (System B, R.sub.T=3.86 min),
ES.sup.+: 313.6 [.sup.35ClMH].sup.+ and 315.6 [.sup.37ClMH].sup.+;
HRMS calcd for C.sub.17H.sub.17ClN.sub.4: 312.1142. found
312.1152.
Example 13
3-(4-Chlorophenyl)-1-[(3S)-tetrahydrofuran-3-yl]-1H-pyrazolo[4,3-c]pyridin-
e
##STR00022##
[0164] Intermediate 1 (200 mg, 0.87 mmol) and triphenylphosphine
(342 mg, 1.31 mmol) were suspended in DCM (5 mL) and
(R)-3-hydroxy-tetrahydrofuran (89 .mu.L, 1.31 mmol) and DIAD (257
.mu.L, 1.31 mmol) were added. The reaction mixture was stirred for
4 h and concentrated in vacuo. The residue was purified by reverse
phase HPLC (YMC ODS-A 100.times.20 mm, 5 .mu.m, 25 mL/min, gradient
60% to 100% (over 7 min) then 100% (3 min) MeOH in 10% MeOH/water)
to give
3-(4-chlorophenyl)-1-[(3S)-tetrahydrofuran-3-yl]-1H-pyrazolo[4,3-c]pyridi-
ne (160 mg, 61.3%) as a colourless gum.
[0165] Analytical HPLC: purity 100% (System B, R.sub.T=4.82 min);
Analytical LCMS: purity 100% (System B, R.sub.T=4.86 min),
ES.sup.+: 300.5 [.sup.35ClMH].sup.+ and 302.5 [.sup.37ClMH].sup.+;
HRMS calcd for C.sub.16H.sub.14ClN.sub.3O: 299.0825. found
299.0835.
Example 14
3-(4-Chlorophenyl)-1-(tetrahydrofuran-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridi-
ne
##STR00023##
[0167] Intermediate 1 (200 mg, 0.87 mmol) and triphenylphosphine
(342 mg, 1.31 mmol) were suspended in DCM (5 mL) and
tetrahydro-3-furan-methanol (126 .mu.L, 1.31 mmol) and DIAD (257
.mu.L, 1.31 mmol) were added. The reaction mixture was stirred for
3 d and concentrated in vacuo. The residue was purified by reverse
phase HPLC (YMC ODS-A 100.times.20 mm, 5 .mu.m, 25 mL/min, gradient
60% to 100% (over 7 min) then 100% (3 min) MeOH in 10% MeOH/water)
to give
3-(4-chlorophenyl)-1-(tetrahydrofuran-3-ylmethyl)-1H-pyrazolo[4,3-c]pyrid-
ine (118 mg, 43.2%) as a colourless gum.
[0168] Analytical HPLC: purity 99.7% (System B, R.sub.T=4.88 min);
Analytical LCMS: purity 100% (System B, R.sub.T=4.94 min),
ES.sup.+: 314.6 [.sup.35ClMH].sup.+ and 316.5 [.sup.37ClMH].sup.+;
HRMS calcd for C.sub.17H.sub.16ClN.sub.3O: 313.0982. found
313.0990.
Example 15
3-(4-Chlorophenyl)-1-(1-ethylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridine
##STR00024##
[0170] Example 5 (162 mg, 0.52 mmol) was dissolved in DMF (5 mL)
and DIPEA (99.0 .mu.L, 0.57 mmol) and iodoethane (46 .mu.L, 0.57
mmol) were added. The reaction mixture was stirred for 11 d and
concentrated in vacuo. The residue was dissolved in MeOH (5 mL),
poured into 1 M aq Na.sub.2CO.sub.3 solution (50 mL) and extracted
with DCM (2.times.50 mL). The combined organic layers were dried
(MgSO.sub.4) and concentrated in vacuo. The residue was purified by
reverse phase HPLC (YMC ODS-A 100.times.20 mm, 5 .mu.m, 25 mL/min,
gradient 60% to 100% (over 7 min) then 100% (3 min) MeOH in 10%
MeOH/water) to give
3-(4-chlorophenyl)-1-(1-ethylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridine
(60 mg, 33.9%) as a colourless gum.
[0171] Analytical HPLC: purity 97.7% (System B, R.sub.T=3.89 min);
Analytical LCMS: purity 100% (System B, R.sub.T=3.94 min),
ES.sup.+: 341.5 [.sup.35ClMH].sup.+ and 343.4 [.sup.37ClMH].sup.+;
HRMS calcd for C.sub.19H.sub.21ClN.sub.4: 340.1455. found
340.1465.
Example 16
3-(4-Chlorophenyl)-1-(1-isopropylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridin-
e
##STR00025##
[0173] Example 5 (257 mg, 0.82 mmol) was dissolved in DCM (10 mL)
and acetone (121 .mu.L, 1.64 mmol), 4 .ANG. molecular sieves (560
mg) and AcOH (1 drop) were added. The reaction mixture was stirred
for 4 h and NaBH(OAc).sub.3 (184 mg, 1.64 mmol) was added. The
reaction mixture was stirred for 16 h. Acetone (200 .mu.L) and
NaBH(OAc).sub.3 (200 mg) were added and the reaction mixture was
stirred for 4 d. 1 M aq Na.sub.2CO.sub.3 (2 mL) was added and the
reaction mixture was stirred for 1 h, poured into 1 M aq
Na.sub.2CO.sub.3 solution (50 mL) and extracted with DCM
(3.times.50 mL). The combined organic layers were dried
(MgSO.sub.4) and concentrated in vacuo. The residue was purified by
reverse phase HPLC (YMC ODS-A 100.times.20 mm, 5 .mu.m, 25 mL/min,
gradient 60% to 100% (over 7 min) then 100% (3 min) MeOH in 10%
MeOH/water) to give
3-(4-chlorophenyl)-1-(1-isopropylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridi-
ne (102 mg, 35.0%) as a colourless gum.
[0174] Analytical HPLC: purity 97.2% (System B, R.sub.T=3.98 min);
Analytical LCMS: purity 100% (System B, R.sub.T=4.05 min),
ES.sup.+: 355.5 [.sup.35ClMH].sup.+ and 357.5 [.sup.37ClMH].sup.+;
HRMS calcd for C.sub.20H.sub.23ClN.sub.4: 354.1611. found
354.1628.
Example 17
3-(4-Fluorophenyl)-1-(1-methylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridine
##STR00026##
[0176] Intermediate 2 (200 mg, 0.94 mmol) and triphenylphosphine
(369 mg, 1.41 mmol) were suspended in DCM (5 mL) and
4-hydroxy-1-methylpiperidine (162 mg, 1.41 mmol) and DIAD (277
.mu.L, 1.41 mmol) were added. The reaction mixture was stirred for
3 d and concentrated in vacuo. The residue was suspended in 1 M HCl
(50 mL), washed with DCM (2.times.30 mL), basified with NaOH and
extracted with DCM (3.times.50 mL). The combined organic extracts
were dried (MgSO.sub.4) and concentrated in vacuo. The residue was
purified by reverse phase HPLC (YMC ODS-A 100.times.20 mm, 5 .mu.m,
25 mL/min, gradient 60% to 100% (over 7 min) then 100% (3 min) MeOH
in 10% MeOH/water) to give
3-(4-fluorophenyl)-1-(1-methylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridine
as a pale yellow gum (35 mg, 12.0%).
[0177] Analytical HPLC: purity 99.5% (System B, R.sub.T=3.50 min);
Analytical LCMS: purity 100% (System B, R.sub.T=3.51 min),
ES.sup.+: 311.5 [MH].sup.+; HRMS calcd for
C.sub.18H.sub.19FN.sub.4: 310.1594. found 310.1602.
Example 18
3-(4-Fluorophenyl)-1-piperidin-4-yl-1H-pyrazolo[4,3-c]pyridine
##STR00027##
[0179] Intermediate 2 (200 mg, 0.94 mmol) and PPh.sub.3 (369 mg,
1.41 mmol) were suspended in DCM (5 mL). N-Boc-4-hydroxypiperidine
(283 mg, 1.41 mmol) and DIAD (277 .mu.L, 1.41 mmol) were added. The
reaction mixture was stirred for 3 d, TFA (2 mL) was added and the
reaction mixture was stirred for 3 h and concentrated in vacuo. The
residue was suspended in 1 M HCl (50 mL), washed with DCM
(2.times.30 mL), basified with NaOH and extracted with DCM
(3.times.50 mL). The combined organic extracts were dried
(MgSO.sub.4) and concentrated in vacuo. The residue was purified by
reverse phase HPLC (YMC ODS-A 100.times.20 mm, 5 .mu.m, 25 mL/min,
gradient 40% to 80% (over 7 min) then 100% (3 min) MeOH in 10%
MeOH/water and YMC ODS-A 100.times.20 mm, 5 .mu.m, 15 mL/min,
gradient 0% to 40% (over 12 min) then 100% (3 min) MeOH+1%
HCO.sub.2H in 10% MeOH/water+1% HCO.sub.2H). The purified fractions
were concentrated in vacuo by half, poured into 1 M aq
Na.sub.2CO.sub.3 solution (50 mL) and extracted with DCM
(3.times.50 mL). The combined organic layers were dried
(MgSO.sub.4) and concentrated in vacuo to give
3-(4-fluorophenyl)-1-piperidin-4-yl-1H-pyrazolo[4,3-c]pyridine as a
colourless gum (67 mg, 24.1%).
[0180] Analytical HPLC: purity 99.1% (System B, R.sub.T=3.44 min);
Analytical LCMS: purity 100% (System B, R.sub.T=3.48 min),
ES.sup.+: 297.6 [MH].sup.+; HRMS calcd for
C.sub.12H.sub.17FN.sub.4: 296.1437. found 296.1449.
Example 19
4-[1-(Tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl]benzonitril-
e
##STR00028##
[0182] Intermediate 4 (275 mg, 1.25 mmol) and PPh.sub.3 (490 mg,
1.87 mmol) were suspended in DCM (5 mL) and
4-hydroxytetrahydropyran (178 .mu.L, 1.87 mmol) and DIAD (368
.mu.L, 1.87 mmol) were added. The reaction mixture was stirred for
18 h and concentrated in vacuo. The residue was purified by reverse
phase HPLC (YMC ODS-A 100.times.20 mm, 5 .mu.m, 25 mL/min, gradient
40% to 80% (over 7 min) then 100% (3 min) MeOH in 10% MeOH/water)
and by column chromatography (normal phase, 20 g, Strata SI-1,
silica gigatube, heptane/EtOAc (1:1) (300 mL) then EtOAc (500 mL))
to give
4-[1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl]benzonitri-
le as a white solid (140 mg, 36.8%).
[0183] Analytical HPLC: purity 99.9% (System B, R.sub.T=4.61 min);
Analytical LCMS: purity 100% (System B, R.sub.T=4.33 min),
ES.sup.+: 305.5 [MH].sup.+; HRMS calcd for
C.sub.18H.sub.16N.sub.4O: 304.1324. found 304.1334.
Example 20
4-[1-(1-Methylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl]benzonitrile
##STR00029##
[0185] Intermediate 4 (275 mg, 1.25 mmol) and PPh.sub.3 (490 mg,
1.87 mmol) were suspended in DCM (5 mL) and
4-hydroxy-1-methylpiperidine (216 mg, 1.87 mmol) and DIAD (368
.mu.L, 1.87 mmol) were added. The reaction mixture was stirred for
18 h and concentrated in vacuo. The residue was dissolved in MeOH
(5 mL), poured into 1 M aq Na.sub.2CO.sub.3 solution (50 mL) and
extracted with DCM (2.times.50 mL). The aq layer was basified with
NaOH and extracted with EtOAc (3.times.50 mL). The combined organic
layers were dried (MgSO.sub.4) and concentrated in vacuo. The
residue was purified by column chromatography (normal phase, 20 g,
Strata SI-1, silica gigatube, DCM/EtOH/NH.sub.3 200:8:1 (300 mL)
then DCM/EtOH/NH.sub.3 100:8:1 (500 mL)) and by reverse phase HPLC
(YMC ODS-A 100.times.20 mm, 5 .mu.m, 15 mL/min, gradient 0% to 30%
(over 12 mM) then 100% (3 min) MeOH+1% formic acid in 10%
MeOH/water+1% formic acid). The residue was dissolved in 1 M aq
Na.sub.2CO.sub.3 solution (25 mL), extracted with DCM (2.times.25
mL), dried (MgSO.sub.4) and concentrated in vacuo to give
4-[1-(1-methylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl]benzonitrile
as a white solid (46 mg, 12.6%).
[0186] Analytical HPLC: purity 99.5% (System B, R.sub.T=3.34 min);
Analytical LCMS: purity 100% (System B, R.sub.T=3.31 min),
ES.sup.+: 318.5 [MH].sup.+; HRMS calcd for C.sub.19H.sub.19N.sub.5:
317.1640. found 317.1649.
Biological Tests
Biological Assay of the SSAO Enzyme Inhibitors
[0187] All assays were performed in room temperature with purified
recombinantly expressed human SSAO. Enzyme was prepared essentially
as described in Ohman et al. (Protein Expression and Purification
2006, 46, 321-331). The enzyme activity was measured with
benzylamine as substrate and utilized the production of hydrogen
peroxide for detection. In a horseradish peroxidise (HRP) coupled
reaction, hydrogen peroxide oxidation of
10-acetyl-3,7-dihydroxyphenoxazine produced resorufin, which is a
highly fluorescent compound (Zhout and Panchuk-Voloshina.
Analytical Biochemistry 1997, 253, 169-174; Amplex.RTM. Red
Hydrogen Peroxide/peroxidise Assay kit, Invitrogen A22188).
[0188] Briefly, test compounds were dissolved in dimethyl sulfoxide
(DMSO) to a concentration of 10 mM. Dose-response measurements were
assayed by either creating 1:10 serial dilutions in DMSO to produce
a 7 point curve or by making 1:3 serial dilutions in DMSO to
produce 11 point curves. The top concentrations were adjusted
depending on the potency of the compounds and subsequent dilution
in reaction buffer (50 mM sodium phosphate, pH 7.4) yielded a final
DMSO concentration.ltoreq.2%. Enzyme and compounds were set to
pre-incubate in flat-bottomed microtiter plates for approximately
60 minutes before initiating the reaction by addition of a mixture
of HRP, benzylamine and Amplex reagent. Fluorescence intensity was
then measured at several time points (15 minutes, 20 minutes and 30
minutes) exciting at 544 nm and reading the emission at 590 nm).
Final concentrations of the reagents in the assay wells were: SSAO
enzyme 2 .mu.g/ml, benzylamine 100 .mu.M, Amplex reagent 20 .mu.M,
HRP 0.1 U/mL and varying concentrations of test compound. The
inhibition was measured as % decrease of the signal compared to a
control without inhibitor (only diluted DMSO). The background
signal from a sample containing no SSAO enzyme was subtracted from
all data points. Data was fitted to a four parameter logistic model
and IC.sub.50 values were calculated using the GraphPad Prism 4 or
XLfit 4 programs.
[0189] The exemplified compounds of the invention generally had an
IC.sub.50 value of 10 to 1000 nM. Obtained IC.sub.50 values for
representative compounds are shown in the table below:
TABLE-US-00001 Compound IC.sub.50 (nM) Example 3 89 Example 5
120
* * * * *